Research Paper Volume 8, Issue 2 pp 304—313
Inhalational Alzheimer's disease: an unrecognized—and treatable—epidemic
- 1 Easton Laboratories for Neurodegenerative Disease Research, Department of Neurology, University of California, Los Angeles, CA 90095, USA
- 2 Buck Institute for Research on Aging, Novato, CA 94945, USA
received: October 30, 2015 ; accepted: February 3, 2016 ; published: February 10, 2016 ;https://doi.org/10.18632/aging.100896
How to Cite
Alzheimer's disease is one of the most significant healthcare problems today, with a dire need for effective treatment. Identifying subtypes of Alzheimer's disease may aid in the development of therapeutics, and recently three different subtypes have been described: type 1 (inflammatory), type 2 (non-inflammatory or atrophic), and type 3 (cortical). Here I report that type 3 Alzheimer's disease is the result of exposure to specific toxins, and is most commonly inhalational (IAD), a phenotypic manifestation of chronic inflammatory response syndrome (CIRS), due to biotoxins such as mycotoxins. The appropriate recognition of IAD as a potentially important pathogenetic condition in patients with cognitive decline offers the opportunity for successful treatment of a large number of patients whose current prognoses, in the absence of accurate diagnosis, are grave.